Bacterial News and Research

RSS

Novel breakthrough may lead to new methods for sterilizing food and medical equipment

Got food poisoning? The cause might be bacterial spores, en extremely hardy survival form of bacteria, a nightmare for health care and the food industry and an enigma for scientists. Spore-forming bacteria, present almost everywhere in our environment, can also cause serious infectious diseases, such as tetanus, anthrax, and botulism.

12 Nov 2009

Medizone International announces new results on Asepticsure sterilization system

Medizone International, Inc. (OTC Bulletin Board: MZEI) announces that following several months of research, AsepticSure(TM) can now achieve a level of bacterial decontamination heretofore unseen in open space settings using conventional means.

11 Nov 2009

Researchers discover cells that protect the respiratory tract from developing an allergic response

According to the great paradigms of immunology, asthma, an allergic disease of the respiratory system, should always develop upon exposure to airborne antigens that are constantly being inhaled. However, the fact that 94 % of the Western population does not develop the disease suggests that as yet undefined mechanisms protect the respiratory tract from developing an allergic response. A team of researchers at University of Liege (Belgium), GIGA Research Center, led by Professor Fabrice Bureau, has shown that asthma is inhibited by regulatory macrophages, a cell population never previously described.

10 Nov 2009

Researcers identify a new array of genes in GAS

Group A streptococcus (GAS) is a human pathogenic bacteria. Many people carry GAS asymptomatically in their upper respiratory tract and other anatomic sites. However, these bacteria can cause a variety of human diseases ranging from superficial skin and throat infections to highly invasive life-threatening diseases such as toxic shock and necrotizing fasciitis, commonly known as the flesh-eating bacteria.

10 Nov 2009

Novartis to acquire 85% stake in Zhejiang Tianyuan Bio-Pharmaceutical for US$125 million

Hard To Treat Diseases (HTDS.PK) www.htdsmedical.com, announced today that Novartis, a US$41 billion international healthcare company, is acquiring an 85% stake in HTDS' H1N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., for US$125 million.

10 Nov 2009

Researchers develop tools to visualize how different cell populations of cells communicate

Using imaging mass spectrometry, researchers at the University of California, San Diego have developed tools that will enable scientists to visualize how different cell populations of cells communicate. Their study shows how bacteria talk to one another - an understanding that may lead to new therapeutic discoveries for diseases ranging from cancer to diabetes and allergies.

9 Nov 2009

Transatlantic task force to address antibiotic resistance established, experts welcome initiative

Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide.

7 Nov 2009

Experts applaud the EU Presidency for establishing a transatlantic task force to address antibiotic resistance

7 Nov 2009

Novexel commences comparative study of NXL103 to oral linezolid

Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI). The trial is designed to assess the safety and efficacy of NXL103 in comparison to oral linezolid.

6 Nov 2009

ImmunoLin provides immediate benefit to the function of immune system and gut

A new study provides evidence that ImmunoLin®, an all natural and GRAS approved source of immunoglobulin, will provide immediate benefit to the function of the immune system and the gut. Immunoglobulins, or antibodies, are specialized proteins found in blood that the immune system naturally produces for immunity.

6 Nov 2009

Inspire Pharmaceuticals reports net loss of $8.5 million for the third quarter ended September 30, 2009

Inspire Pharmaceuticals, Inc. announced today financial results for the third quarter ended September 30, 2009, reporting a net loss of $8.5 million or ($0.12) per common share.

5 Nov 2009

Foamix' emollient foam platform awarded Mexican patent

Foamix Ltd., a leading developer of topical foams for dermatological and gynecological use, announced today that it has been awarded Mexican Patent Registration No. 268451 entitled "Cosmetic and Pharmaceutical Foam." The patent covers Foamix's vehicles, compositions and cosmetic and pharmaceutical uses thereof based on the company's Emollient Foam technology platform.

4 Nov 2009

Report on the global anti-infectives market

MarketResearch.com has announced the addition of Kalorama Information's new report "The Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)," to their collection of Healthcare market reports.

4 Nov 2009

Raycop's anti-bacterial vacuum cleaning system with UVC technology kills the H1N1 virus

Raycop, the first handheld anti-bacterial vacuum cleaning system and part of the Earlex® brands, offers a proven way to fight the H1N1 virus in the home with its UVC technology. The vac's effects against the virus have been independently tested by a leading international laboratory in August.

3 Nov 2009

Pulmatrix raises $30.2 million through Series B financing

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the treatment and prevention of infectious and progressive respiratory diseases, today announced that it has secured $30.2 million in Series B financing. ARCH Venture Partners and Novartis Bioventures Fund co-led the round with participation from existing investors Polaris Venture Partners and 5AM Ventures.

2 Nov 2009

Exposure to mercury-based preservative in vaccines is minimal, says researchers

The injectable, multi-dose H1N1 vaccine contains the mercury-based preservative thimerosol to reduce risks of bacterial contamination. The presence of thimerosol has once again raised concerns whether there are risks posed to children when the tiny amount of mercury contained in thimerosol is included in a vaccine.

31 Oct 2009

Study indicates possibility of a vaccine to prevent Group B Streptococcus infection

Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have completed a Phase II clinical study that indicates a vaccine to prevent Group B Streptococcus (GBS) infection is possible. GBS is the most common cause of sepsis and meningitis in newborns in the United States, according to the Centers for Disease Control and Prevention (CDC). It can also cause severe illness in pregnant women, the elderly and adults with chronic illnesses.

31 Oct 2009

ATLANTA-France study of the CATANIA Coronary Stent announced

Physicians at more than 40 centers in France have joined a study of the CATANIA(TM) Coronary Stent with NanoThin Polyzene®-F manufactured by CeloNova BioSciences. With Professor Emmanuel Teiger and Doctor Paul Barragan as co-Principal Investigators, the researchers today announced the Assessment of The Latest Non-Thrombogenic Angioplasty (ATLANTA-France) stent study. Each center will enroll 50 patients with the first procedures expected in early November.

31 Oct 2009

130 million children to be immunised against pneumonia

Marking the first international World Pneumonia Day on 2 November, the GAVI Alliance plans to immunise 130 million children in poor countries against pneumonia, the world's leading child killer.

30 Oct 2009

Bacterial or viral skin infections continue to grow among high school and college athletes, survey reveals

A recent survey of nearly 650 athletic trainers across the U.S. revealed that in the past 12 months nearly 76 percent of the respondents' athletic programs, mostly high school- and college-based, bacterial or viral skin infections have developed.

30 Oct 2009

Bacterial News and Research

Novel breakthrough may lead to new methods for sterilizing food and medical equipment

Medizone International announces new results on Asepticsure sterilization system

Researchers discover cells that protect the respiratory tract from developing an allergic response

Researcers identify a new array of genes in GAS

Novartis to acquire 85% stake in Zhejiang Tianyuan Bio-Pharmaceutical for US$125 million

Researchers develop tools to visualize how different cell populations of cells communicate

Transatlantic task force to address antibiotic resistance established, experts welcome initiative

Experts applaud the EU Presidency for establishing a transatlantic task force to address antibiotic resistance

Novexel commences comparative study of NXL103 to oral linezolid

ImmunoLin provides immediate benefit to the function of immune system and gut

Inspire Pharmaceuticals reports net loss of $8.5 million for the third quarter ended September 30, 2009

Foamix' emollient foam platform awarded Mexican patent

Report on the global anti-infectives market

Raycop's anti-bacterial vacuum cleaning system with UVC technology kills the H1N1 virus

Pulmatrix raises $30.2 million through Series B financing

Exposure to mercury-based preservative in vaccines is minimal, says researchers

Study indicates possibility of a vaccine to prevent Group B Streptococcus infection

ATLANTA-France study of the CATANIA Coronary Stent announced

130 million children to be immunised against pneumonia

Bacterial or viral skin infections continue to grow among high school and college athletes, survey reveals

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News